Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:05 2024-05-10 am EDT			5-day change	1st Jan Change
8.63 ^EUR	+0.23%		+1.89%	-25.22%

Apr. 24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Adocia: announces fund-raising	CF

Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2021

April 19, 2022 at 12:00 pm EDT

Adocia SA reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 1.44 million compared to EUR 0.841 million a year ago. Revenue was EUR 6.06 million compared to EUR 6.83 million a year ago. Net loss was EUR 22.75 million compared to EUR 23.32 million a year ago.

Latest news about Adocia

Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Adocia: announces fund-raising	Mar. 22	CF
Adocia SA announced that it expects to receive ?2 million in funding	Mar. 20	CI
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes	Nov. 09	CI
Adocia: positive study data for BC Combo	23-10-23	CF
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-18	CI
Adocia: refinancing operations completed	23-07-26	CF
Adocia SA announced that it has received ?9.999993 million in funding from Bpifrance Investissement SAS, Vester Finance SA	23-07-19	CI
Adocia: exclusive right to negotiate M1Pram with Sanofi	23-07-06	CF
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug	23-07-06	MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram	23-07-05	CI
Adocia SA announced that it expects to receive â‚¬10 million in funding	23-07-04	CI
Adocia Requests Trading Halt on Euronext Paris	23-06-01	MT
Adocia: listing suspended pending a press release	23-06-01	CF
Adocia SA Auditor Raises 'Going Concern' Doubt	23-04-27	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	23-03-16
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Adocia: CDC drops below 10% stake	23-01-20	CF
Adocia Jumps 11% as BioChaperone Lispro Shows Faster Absorption in Early-stage Insulin Injection Trial	22-12-29	MT
Adocia: share price rises on positive study results	22-12-29	CF
Adocia SA Announces the Successful Phase 1 Study for Biochaperone® Lispro with Partner Tonghua Dongbao	22-12-29	CI
Adocia SA announced that it has received €5.999997 million in funding	22-10-30	CI
Adocia's Phase 2 Study of M1Pram Shows Better Weight Loss, Appetite Control in Diabetic Obese People; Shares Surge 13%	22-10-06	MT
Adocia Sa Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes Using M1pram in A Post-Hoc Analysis	22-10-06	CI
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI

Chart Adocia

Duration

Period

More charts

Company Profile

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Equity Spring Forum

More about the company

Income Statement Evolution

More financial data

Ratings for Adocia

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.63 EUR

Average target price

9.7 EUR

Spread / Average Target

+12.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADOCIA	-25.22%	133M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs